Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer | NEJM
Update on systemic treatment for newly diagnosed inflammatory breast cancer - ScienceDirect
Adjuvant endocrine therapy is associated with improved overall survival in elderly hormone receptor-positive breast cancer patients | SpringerLink
PDF) Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton
Impact of deviation from guideline recommended treatment on breast cancer survival in Asia | Scientific Reports
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis - The Lancet Oncology
IJMS | Free Full-Text | Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis | HTML
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort - ESMO Open
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study | Scientific Reports
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial - Annals of Oncology
Endocrine therapy or chemotherapy as first-line therapy in hormone receptor–positive HER2-negative metastatic breast cancer patients - European Journal of Cancer
Real world initial palliative treatment patterns and clinical outcomes in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A study of the National Cancer Center, China - ScienceDirect
Survival analysis of bevacizumab plus taxane treatment in luminal metastatic breast cancer | Future Science OA
Real-world Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis | Scientific Reports
Breast Cancer Survival Rate: Prognosis by Age and More
Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment. - Abstract - Europe PMC
Survival in patients with HR+/HER2− metastatic breast cancer treated with initial endocrine therapy versus initial chemotherapy. A French population-based study | British Journal of Cancer
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort - ESMO Open
Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline | Journal of Clinical Oncology
Chemo or Hormone Therapy Result in Similar Survival for Women with Breast Cancer - CancerConnect
Endocrine therapy or chemotherapy as first-line therapy in hormone receptor–positive HER2-negative metastatic breast cancer patients - European Journal of Cancer
Tumour Cell Secretome in Chemoresistance and Tumour Recurrence: Trends in Cancer
In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium - Annals of Oncology
Real world initial palliative treatment patterns and clinical outcomes in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A study of the National Cancer Center, China - ScienceDirect
Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis
